Alkem Eyes JB Pharma Acquisition After Torrent Withdraws from Deal
Alkem Pursues JB Pharma Acquisition
India’s fifth largest drugmaker Alkem Laboratories is making a strategic move to acquire JB Chemicals and Pharmaceuticals as private equity player KKR and others aim to cash out. Recent developments indicate that Torrent Pharmaceuticals, previously the frontrunner for the $3-billion acquisition, has exited negotiations due to valuation differences.
Background on Recent Developments
Moneycontrol reported that late on September 12, the Singh family, promoters of Alkem, have initiated talks to sell a significant stake in the company to private equity firms. Having engaged with Nomura for assistance in finding buyers, Alkem's leadership may be open to divesting a controlling interest in this key player in the pharmaceutical sector.
Alkem's Market Position
Alkem holds a strong market presence, particularly in sectors like anti-infectives, pain management drugs, and gastrointestinal treatments. Furthermore, their portfolio includes a range of products targeting chronic conditions such as diabetes, neurology, and cardiology.
- Alkem is a leader in anti-infectives.
- Recent talks suggest a significant shift in pharmacy acquisitions.
- Strategic maneuvers by the Singh family may reshape market dynamics.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.